Oura’s indefinite postponement of its planned late-September 2026 Nasdaq IPO, which targeted a $15.6 billion valuation and up to $2.2 billion in proceeds at a $40–$44 share range, underpins the 95.7% market-implied odds of no listing before January 2027. The company cited IPO-market uncertainty despite strong initial demand and cornerstones from firms such as Dragoneer and Eli Lilly, electing to wait given its profitability and expected 90% revenue growth for fiscal 2026. With a private valuation near $11 billion from the prior Series E and continued subscriber expansion to roughly six million paid members, Oura retains flexibility on timing. A clearer path to an offering would require sustained improvement in equity-market sentiment or a fresh SEC filing that accelerates roadshow activity before year-end.
基於Polymarket數據的AI實驗性摘要。這不是交易建議,也不影響該市場的結算方式。 · 更新於1H6H1D7D30DALL
View resolved

警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions